Myriad’s myPlan Lung Cancer Test Meets Primary Endpoint in Trial – Benzinga

by lowes1 on September 25, 2013

Myriad's myPlan Lung Cancer Test Meets Primary Endpoint in Trial
Benzinga
SALT LAKE CITY, Sept. 25, 2013 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq: MYGN) today announced new data published in Clinical Cancer Research that showed the myPlan Lung Cancer test is a significant predictor of lung cancer death in 
Myriad Genetics, Inc. (MYGN): Myriad's lung cancer test meets primary endpoint Seeking Alpha

all 2 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: